Search

Your search keyword '"Beaujard, Annie C."' showing total 4 results
Start Over Author "Beaujard, Annie C."
4 results on '"Beaujard, Annie C."'

2. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis

Author

Beaujard, Annie C, Glehen, Olivier, Caillot, Jean L, Francois, Yves, Bienvenu, Jacques, Panteix, Gilles, Garbit, Florence, Grandclement, Eric, Vignal, Jacques, and Gilly, Francois, N

Subjects
Pelvic cancer -- Care and treatment, Hyperthermia treatment systems (Medical care) -- Evaluation, Mitomycin -- Health aspects, Gastrointestinal cancer -- Care and treatment, Health
Published
2000

4. Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C.

Author

Sayag-Beaujard AC, Francois Y, Glehen O, Sadeghi-Looyeh B, Bienvenu J, Panteix G, Garbit F, Grandclément E, Banssillon V, Vignal J, and Gilly FN

Subjects
Adult, Aged, Ascites therapy, Carcinoma drug therapy, Carcinoma mortality, Combined Modality Therapy, Female, Gastrointestinal Neoplasms mortality, Humans, Male, Middle Aged, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms mortality, Survival Rate, Antibiotics, Antineoplastic therapeutic use, Carcinoma therapy, Gastrointestinal Neoplasms complications, Hyperthermia, Induced methods, Mitomycin therapeutic use, Peritoneal Neoplasms therapy
Abstract

Peritoneal carcinomatosis in patients with digestive cancer carries a poor prognosis, with a majority of patients dying within 6 months. Mitomycin C has been reported to have some antitumor efficacy in this setting. We performed combination intraperitoneal hyperthermia and mitomycin to potentiate the effect of mitomycin C in 83 patients with peritoneal involvement due to digestive cancers. Eighty six IPCH procedures were performed using inflow temperature 46 to 49 degrees Celsius, using a closed circuit, during 90 minutes. Mitomycin C was administered as a perfusate at 10 mg/l. Primary tumors were essentially gastric (42) and colorectal (27). Mortality and morbidity rates were 3/83 and 5/83 respectively. For resectable tumors, the median survival time was 16 months in stage 1 and 2 carcinomatosis (malignant granulations less than 5 mm in diameter). For resectable gastric cancers with stage 1 and 2 carcinomatosis, one, two and three year actuarial survival rates were 80, 61 and 41% respectively. In conclusion, IPCH appears to be an interesting therapeutic option in patients with digestive cancers and small malignant peritoneal granulations (stage 1 and 2).

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results